Skip to content

Effect of Mediterranean Diet in Inflammatory Bowel Disease

Implementing Metabolomics Informed Diet on Inflammatory Bowel Disease Patients

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05973500
Enrollment
90
Registered
2023-08-03
Start date
2023-09-01
Completion date
2028-08-01
Last updated
2024-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Disease

Brief summary

The effects of diet on inflammatory bowel disease is an under-studied area of research. The investigators are interested in further investigating the role that diet contributes to inflammatory bowel disease severity. The investigators will collect blood and stool samples from patients with inflammatory bowel disease (IBD) before and after diet changes. The stool samples will be analyzed using metabolomics and microbiome analysis to determine changes after the new diet has been implemented. The investigators will then compare changes in the patient's overall disease state by measuring markers of inflammation including C-reactive protein (CRP) and fecal calprotectin to determine how this diet affects the disease state.

Interventions

DIETARY_SUPPLEMENTMediterranean Diet

Mediterranean Diet for 42 Days

Sponsors

University of California, San Diego
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years old or older * Meet classification criteria for inflammatory bowel disease including those with mild to moderate Crohn's Disease as defined by a Crohn's disease activity index between 150-450, with fecal calprotectin\>250, within 1 month of enrollment.

Exclusion criteria

* Unable to provide informed consent * History of or current drug abuse * Pregnancy * Start or change in dose of standard-of-care treatment within 12 weeks of the screening * Known allergy to any component of the proposed diet * Subjects with significant other medical or psychiatric comorbidities and /or medication use which in * physician's clinical judgment might difficult the interpretation of the results * Patients that are not on a stable dose of medications, for instance, steroids, in between samples collection * Patients on antibiotics * Patients with C difficile infection within 4 weeks of enrollment

Design outcomes

Primary

MeasureTime frameDescription
short Crohn's Disease Activity Index (sCDAI)42 DaysMild to moderate Crohn's Disease is defined by a short Crohn's Disease activity index (sCDAI) between 150-450, while those in remission from Crohn's Disease have an sCDAI score below 150. An sCDAI score exceeding 450 is used as a marker of severe Crohn's Disease.

Countries

United States

Contacts

Primary ContactMonica Guma, M.D., PhD
mguma@health.ucsd.edu8588226523
Backup ContactMehrnaz Aghili, M.D.
maghili@health.ucsd.edu8582464721

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026